Puberty Blockers

Joy Morrissey Excerpts

Tuesday 23rd June 2026 Commons Chamber

[Alison Bennett]

I am afraid that I will not.

Liberal Democrats have been arguing for many years that improved access to better specialist healthcare services for children and young people struggling with their gender identity is extremely important. Those young people have been badly let down by low care standards and extremely long waiting lists. The closure of the Gender Identity Development Service made it clear beyond doubt that change was needed. We have consistently campaigned for real action to tackle the shocking waiting times across the NHS, including for gender identity services.

Liberal Democrats welcome the move to create new regional centres to offer this care to the young people who need it. There is a need for multiple geographically dispersed clinics so that care is closer to those who need it, but roll-out has been slow, and more needs to be done to tackle the waiting lists—quite simply, a three-year average wait is not acceptable. For the centres to run effectively, we must support the specialists who provide children and young people with high-quality, compassionate and clinically appropriate care.

Treatment, first and foremost, should be based on talking therapies. Space and time to talk through feelings is vital for young people struggling with their gender identity. It is a deeply complex set of feelings, and questioning and understanding one’s identity is never an easy thing, especially for a child, but for talking therapies to be an effective first step, children must be able to access them when they need them, not after years on a waiting list.

The debate is about access to a form of healthcare—one that is led by doctors and clinicians—and, as for any other form of healthcare, we must listen to the experts: the people who have spent years training and years delivering care.

[Joy Morrissey (Beaconsfield) (Con)]

Will the hon. Member give way?

[Alison Bennett]

I will not.

We must never lose sight of the fact that at the core of the debate is young people’s wellbeing and health. It is not about ideology; it is about what is best for young people. The Government must always prioritise clinical evidence and put the interests of patients at the heart of care.

--- Later in debate ---

[Joy Morrissey]

Will the hon. Lady give way?

[Sarah Owen]

I am not going to take any more interventions, as I have been told that I need to crack on.

These puberty blockers are the same drugs, prescribed in the same way, but instead of treating gender distress, they are treating prostate cancer, endometriosis and premature sexual maturity in children. Yet we have heard no call from scientists, campaigners or the medical community to stop the use of puberty blockers for those treatments.

Some have been critical of the trial going ahead, but what happens to young people experiencing gender distress if it does not? Dr Hilary Cass believes that without a trial, young people will continue to get drugs from “unregulated and dangerous routes”, and my Select Committee heard evidence to support that. Unfortunately, young people are now self-treating because they see no other option. They are getting hold of medication from abroad, with no assessment, support or medical advice. Dr Hilary Cass was right to say that she is

“absolutely convinced that more children will be harmed if we don’t do the trial than if we do.”

For me, safety is paramount, but this is an issue of access to healthcare, and there should never be a block to healthcare for anyone. While the trial goes forward, many young people, younger and older, will be scared and frightened about what the future holds. I hope that the Secretary of State can address the hostile environment for young trans people, as well as what support outside of legislation and the medical world needs to be more widely available for people in gender distress and the entire LGBTQ+ community.

--- Later in debate ---

[Joy Morrissey (Beaconsfield) (Con)]

The reason I am in the Chamber today is the protection of children—that is why I care about banning social media, and it is why I am here to speak about puberty blockers. We protect young people under the age of consent from alcohol, heroin and sexual abuse, because they are children under the age of 18. This puberty blockers trial for 11-year-olds makes me ask whether we are putting sufficient safeguards in place for those young people, and whether they have the cognitive ability to understand what they are doing. Do they have the cognitive development to understand that, when their brain is fully developed, they will have made an irreversible choice, one that will last for the rest of their lives?

We talk about these children giving consent. What about a class action lawsuit? Members have referred to 7% of people being happy to continue with the therapy. What will happen when these children are 18 or 25? Inevitably, a percentage will decide that they do not want to continue in the gender they chose as a child and want to go back to the gender they were before. What are they going to do? Are they going to sue the Government? Are they going to sue the clinicians for conducting the trial, because they were forced and coerced into something that they did not fully understand?

[Danny Beales]

I thank the hon. Member, my constituency neighbour, for giving way on that point. There is a lot of “what about” in her remarks; will she reflect on Dr Hilary Cass’s comments that the trial will lead to less harm than would otherwise be the case? Why does she believe that Dr Cass is saying that? Does she doubt her expertise in this instance?

[Joy Morrissey]

My doubts come from why, for example, we are not allowing the data linkage study to be fully completed before proceeding with the new trial. That study would find out what has happened to all the children who have already taken puberty blockers. I wanted to ask the Liberal Democrat spokesperson, the hon. Member for Mid Sussex (Alison Bennett), that question, but I was not able to make that intervention; I do not know whether that had anything to do with the £1.5 million donation from Ferring Pharmaceuticals that the Lib Dems took before the 2019 election. I do not know whether that had anything to do with it, but there has to be some level of declaration if a political party has taken donations from a pharmaceutical company that is promoting this drug. That is relevant to how one represents oneself in the Chamber.

There is no justification for proceeding with the Pathways trial before the data linkage study is complete. Puberty is how a child transitions from childhood to adulthood, and anything that affects that process is going to have long-term effects. Those effects are going to be felt, not in one or two years, but in 10 years. The brains we have as adults, at the age of 24, are very different from the brains we have as 11-year-olds—our frontal cortexes are not fully developed. This is not just about the effect on these children’s psychology; what effects do these drugs have on humans over the long term? We do not know that, so why not look at the data linkage study? It does not have to be perfect, but it will allow us to protect the children going into this trial, so that the trial is as well-run as possible.

[Iqbal Mohamed]

I thank my hon. Friend for giving way, and for making such a passionate speech. I think we all agree, across the House, that we are here not to politicise or to demonise, but to try to make the right decisions for the safety of children. I think that all Members here share that intention. It was said earlier that these drugs are already used to treat different conditions, such as prostate cancer, endometriosis and precocious puberty. For the first two conditions they are taken by adults for a very short time, and for the third they are taken for a limited period until the child reaches the age of puberty. Such misinformation—or comparison—is not really valid, and should be avoided.

[Joy Morrissey]

That is an excellent point. When I heard about those other uses for the drug, I thought that I would be interested to see more clinical trials for conditions such as endometriosis and cancer to establish its long-term effects. However, that is for adults. When it comes to protecting children, I want to ensure that this trial involves as much safeguarding as possible.

We do not fully understand the long-term risk. We come to the House again and again to discuss what constitutes a child and what constitutes protecting a child. We need to be clear about the fact that we must protect people under the age of 16, or 18—I do not care which age it is, but it should be an age on which we all agree—and that they must be subject to extra protection and safeguarding until they reach adulthood. That is why we are asking for so many safeguards—we need to ensure that the unintended consequence of trying to help a few young people does not lead to greater harm to many—and it is why we are here today.

I do not feel that asking the Government to include the data linkage study is too much to ask. This trial is a trade-off: long-term health is being exchanged for short-term happiness. This trial, in my opinion, is not safe, and this trial will not protect children from harm.